Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Royalty Pharma experienced a landmark year in 2025, achieving a top-line growth of 14%-16% and announcing $4.7 billion in royalty transactions, while the royalty market reached a record high of $10 billion [2][3][5]. Company Performance - The company internalized its external manager, leading to cost savings and improved governance, and is on track to meet its 2025 guidance for Portfolio Receipts of $3,200 to $3,250 million [6][7]. - Royalty Pharma achieved a Return on Invested Capital of 15.7% and a Return on Invested Equity of 22.9% on a trailing twelve-month basis [7]. Industry Trends - The royalty funding market saw a 40% increase in total value, reaching $10 billion in 2025, compared to an average of $7.1 billion over the previous five years [3][4]. - Synthetic royalties, a concept pioneered by Royalty Pharma, accounted for $4.7 billion of the total market value, highlighting their growing acceptance in the biopharma capital structure [4][5]. Future Outlook - The company anticipates continued favorable industry conditions in 2026, supported by a robust pipeline of potential transactions and several important milestones in its development-stage portfolio [2][10]. - Royalty Pharma expects to achieve at least $4.7 billion in Portfolio Receipts by 2030, implying a growth rate of 9% or greater from 2025 to 2030 [9]. Development Pipeline - The company’s pipeline includes 20 development-stage therapies, with several expected to achieve pivotal milestones in 2026, including daraxonrasib, litifilimab, and pelacarsen [11][12]. - The late-stage pipeline therapies have the potential for combined peak sales exceeding $43 billion annually, translating to over $2.1 billion in new royalties for Royalty Pharma [12].